AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 182 min read$NKTR

ROBIN HOWARD W sold $1.2M of NKTR

ROBIN HOWARD W (President & CEO) sold 20,000 shares of NEKTAR THERAPEUTICS (NKTR) at an average of $60.75 ($59.97–$61.65, $1.22M total) across 4 trades over 2026-06-16 to 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROBIN HOWARD W
Published Jun 18, 2026, 11:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 18, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NKTR
Neutral
medium confidence
Mentioned
$NKTR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NKTRNeutralLow
01

Why it matters

The newest concrete fact is the CEO’s open-market sale of 20,000 shares (about $1.22M) across four trades at ~$59.97–$61.65, with holdings after the sale of 55,045 shares.

02

Market read

Traders may monitor NKTR for follow-on insider activity, but this filing alone is not a fundamental catalyst.

03

What to watch

Insider sales can be driven by diversification/taxes; without additional context (e.g., option exercises, other filings, or guidance changes), the trading signal is weak.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-18 (after-hours/late day disclosure).

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for NeKTAR Therapeutics (NKTR).

Company-level read

Ticker impact

$NKTRNeutralMedium confidence
Context

NeKTAR Therapeutics CEO Robin Howard W sold about $1.22M of NKTR shares via an open-market sale under a 10b5-1 plan (Form 4 filed today).

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a new catalyst.

Evidence & confidence

The filing is a routine Form 4 insider transaction with a stated 10b5-1 pre-arranged plan and no accompanying operational/regulatory/financial update in the text.

Market effects

Sector

None indicated; this is company-specific insider activity in biotech/pharma.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may be mechanically scheduled and not a signal of negative outlook.

Key entities

  • company
    NeKTAR Therapeutics

    Issuer of the Form 4 insider transaction; CEO Robin Howard W sold shares under a 10b5-1 plan.

  • insider
    Robin Howard W

    President & CEO and reporting person who executed the open-market sales.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NKTR insider trading history →

Related articles

OCT 8
$LLYLow

Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

mondaq.com2 min
OCT 7
$NKTRLow

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

Nektar Therapeutics (NKTR) won a $115 million lawsuit against Eli Lilly (LLY), resolving a multi-year overhang. The verdict, including interest, amounts to ~5% of NKTR's market cap. Despite the win, NKTR's stock fell over $200 million in market cap due to market volatility and rising yields. Cedar Grove Capital Management views this as a net positive for NKTR, removing a long-standing uncertainty.

finance.yahoo.com2 min
OCT 1
$NKTRMedAI 8/10

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Nektar Therapeutics (NKTR) shares fell 21% after reporting modest new response rates for its experimental skin drug, rezpegaldesleukin, in alopecia and eczema studies. Despite this, analysts at William Blair and Jefferies maintained bullish ratings, citing the drug's durability advantage. The company also faces an ongoing legal dispute with Eli Lilly.

newsable.asianetnews.com2 min